AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 201 min read$ARTV

Banerjee Subhashis sold $5K of ARTV

Banerjee Subhashis (Chief Medical Officer) sold 429 shares of Artiva Biotherapeutics, Inc. (ARTV) at $12.00 on 2026-08-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Banerjee Subhashis
Published Aug 20, 2026, 1:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 1:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ARTV
Neutral
high confidence
Mentioned
$ARTV
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVNeutralLow
01

Why it matters

The transaction is a routine insider sale with limited market impact.

02

Market read

Low relevance; typical insider transaction with minimal price effect.

03

What to watch

Potential upcoming clinical data releases could change relevance of insider activity.

Relevance 2/10Novelty 4/10Timing: post-filing 2026-08-19

Background

Artiva Biotherapeutics filed a Form 4 reporting a $5K sale by its CMO under a pre‑arranged 10b5‑1 plan.

Company-level read

Ticker impact

$ARTVNeutralHigh confidence
Context

Form 4 disclosed Chief Medical Officer Banerjee Subhashis sold 429 shares for $5,148 via a 10b5-1 plan.

Expected impact

minimal impact, price likely unchanged

Evidence & confidence

Sale size is small relative to total holdings and market cap; typical for 10b5-1 plans.

Market effects

Sector

None; biotech sector not affected by a small insider transaction.

Regional

None; transaction is company‑specific.

Global

None

Counterpoint

What could challenge this read

Even small insider sales can signal concerns; monitor upcoming disclosures.

Key entities

  • Company
    Artiva Biotherapeutics, Inc.

    Biotech firm developing therapies.

  • Executive
    Banerjee Subhashis

    Chief Medical Officer of Artiva.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ARTV insider trading history →

Related articles

OCT 27
$ARTVLow

Artiva Biotherapeutics, Inc. (ARTV): Results of Operations and Financial Condition

Artiva Biotherapeutics, Inc. (ARTV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK ® • Company halting further development of AlloNK ® (AB-101), including the planned phase 3 pivotal trial • Updated deep B cell depletion and clinical response data is consistent

SEC EDGAR 8-K2 min
OCT 27
$ARTVHighAI 8/10

Why is Artiva Biotherapeutics stock collapsing today?

Artiva Biotherapeutics' stock fell 30% after halting AlloNK (AB-101) development due to safety events and poor clinical data. The company plans to cut 94% of its workforce and explore strategic alternatives, including liquidation. CEO and COO sold shares before the announcement. Artiva had $319.1M in cash as of September 30. The stock traded at $4.31, far below its 52-week high of $14.53.

investing.com2 min